Article Details
Retrieved on: 2024-02-05 18:34:47
Tags for this article:
Click the tags to see associated articles and topics
Summary
Innovent Biologics, a biopharmaceutical company specializing in treatments including cancer immunotherapy and monoclonal antibodies, announces CFO retirement and appointment amid continuous capital market growth. This relates to their portfolio of specialty and orphan drugs like Sintilimab.
Article found on: finance.yahoo.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here